Results 241 to 250 of about 402,660 (356)

Glial-Dopamine crosstalk: Astrocytic and microglial gatekeepers of neuroinflammation, plasticity, and motivation. [PDF]

AIMS Neurosci
Naffaa MM.
europepmc   +1 more source

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

In vivo Effects of Acute Inflammatory Responses on Dopaminergic Receptor Expression in Leukocytes and Marginal Effects of Hypoxia Pretreatment.

Neuroimmunomodulation
Fleige L, Jakobs M, Brüggemann G, Tebbe B, Martin Schäper T, Engler H, Friedel AL, Hörbelt-Grünheidt T, Fandrey J, Schedlowski M, Capellino S.   +10 more
europepmc   +1 more source

The Brain-Gut Axis in Parkinson's Disease Pathology. [PDF]

Compr Physiol
Ozkaya KS, Browning KN.
europepmc   +1 more source

The role of axonopathy in Parkinson\u27s disease [PDF]

, 2010
O’Malley, Karen L
core   +1 more source

Multimodal Treatment of Neck Pain in Multiple System Atrophy

Movement Disorders Clinical Practice, EarlyView.
Bianca Caliò, Svenja Schmidt, Alessandra Fanciulli   +2 more
wiley   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

Protective Effect of Placental Mesenchymal Stromal Cells in an In Vitro Model of Parkinson's Disease Using Differentiated Neuroblastoma Cells. [PDF]

Int J Mol Sci
Coto-Vilcapoma A, Sánchez-Carretero L, Arenas-Gonzalez D, Molina JA, Morán-Jiménez MJ, Merino JJ, Torre P, Flores AI.   +7 more
europepmc   +1 more source

Reply: To Exercise at High Intensity Heart Rate or Not to Exercise at High Intensity Heart Rate?

Movement Disorders Clinical Practice, EarlyView.
Lennard I. Boon, Amit Batla, Kailash P. Bhatia   +2 more
wiley   +1 more source

Risk‐Benefit Considerations in Deep Brain Stimulation Discontinuation for Late‐Stage Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Management of deep brain stimulation (DBS) in late‐stage Parkinson's disease (LSPD) remains challenging, particularly when deciding whether to continue or discontinue stimulation, and evidence on risk–benefit considerations is limited. Objectives To identify key factors to improve decision‐making in DBS management for LSPD patients.
Pietro Antenucci, Andrea Gozzi, Fabiana Colucci, Federica Pes, Jay Guido Capone, Alba Scerrati, Michele Alessandro Cavallo, Maura Pugliatti, Daniela Gragnaniello, Mariachiara Sensi   +9 more
wiley   +1 more source